Submitted:
09 October 2024
Posted:
10 October 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Setting
2.3. Study Population
2.4. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
6. Limitations
Author Contributions
Funding
Conflicts of Interest
References
- Pericàs JM, Llopis J, Athan E. et al. Prospective cohort study of infective endocarditis in people who inject drugs. J Am Coll Cardiol 2021, 77, 544–55. [Google Scholar] [CrossRef] [PubMed]
- Silverman M, Slater J, Jandoc R. et al. Hydromorphone and the risk of infective endocarditis among people who inject drugs: a population-based, retrospective cohort study. Lancet Infect Dis 2020, 20, 487–97. [Google Scholar] [CrossRef] [PubMed]
- Rudasill SE, Sanaiha Y, Mardock AL. et al.. Clinical outcomes of infective endocarditis in injection drug users. J Am Coll Cardiol 2019, 73, 559–70. [Google Scholar] [CrossRef] [PubMed]
- Suzuki J, Johnson JA, Montgomery MW. et al.. Long-term outcomes of injection drug-related infective endocarditis among people who inject drugs. J Addict Med 2020, 14, 282–6. [Google Scholar] [CrossRef]
- Huggins JP, Hohmann S, David MZ. . Infective endocarditis: a retrospective study of patient characteristics and risk factors for death in 703 United States cases, 2015–2019. Open Forum Infect Dis 2021, 8, ofaa628. [Google Scholar] [CrossRef]
- Falade-Nwulia O, Irvin R, Merkow A. et al.. Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. J Subst Abuse Treat 2019, 100, 45–51. [Google Scholar] [CrossRef]
- Muncan B, Walters SM, Ezell J, Ompad DC. . “They look at us like junkies”: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J 2020, 17, 53. [Google Scholar] [CrossRef]
- Balayan T, Oprea C, Yurin O. et al.. People who inject drugs remain hard-to-reach population across all HIV continuum stages in Central, Eastern and South Eastern Europe—data from Euro-guidelines in Central and Eastern Europe Network. Infect Dis (Lond) 2019, 51, 277–86. [Google Scholar] [CrossRef]
- Shah M, Wong R, Ball L. et al.. Risk factors of infective endocarditis in persons who inject drugs. Harm Reduct J 2020, 17, 35. [Google Scholar] [CrossRef]
- Weber C, Gassa A, Eghbalzadeh K. et al.. Characteristics and outcomes of patients with right-sided endocarditis undergoing cardiac surgery. Ann Cardiothorac Surg 2019, 8, 645–53. [Google Scholar] [CrossRef]
- Goodman-Meza D, Weiss RE, Gamboa S. et al. Long term surgical outcomes for infective endocarditis in people who inject drugs: a systematic review and meta-analysis. BMC Infect Dis. 2019, 19, 918. [Google Scholar]
- Rosenthal, E.S.; Karchmer, A.W.; Theisen-Toupal, J.; Castillo, R.A.; Rowley, C.F. Suboptimal Addiction Interventions for Patients Hospitalized with Injection Drug Use-Associated Infective Endocarditis. Am J Med. 2016, 129, 481–485. [Google Scholar] [CrossRef]
- Hartnett KP, Jackson KA, Felsen C. et al. Bacterial and Fungal Infections in Persons Who Inject Drugs - Western New York, 2017. MMWR Morb Mortal Wkly Rep. 2019, 68, 583–586. [Google Scholar] [CrossRef]
- Kim JB, Ejiofor JI, Yammine M. et al. Surgical outcomes of infective endocarditis among intravenous drug users. J Thorac Cardiovasc Surg. 2016, 152, 832–841.e831. [Google Scholar] [CrossRef] [PubMed]
- Rodger L, Glockler-Lauf SD, Shojaei E. et al. Clinical Characteristics and Factors Associated With Mortality in First-Episode Infective Endocarditis Among Persons Who Inject Drugs. JAMA Netw Open. 2018, 1, e185220. [Google Scholar] [CrossRef] [PubMed]
- Njoroge, L.W.; Al-Kindi, S.G.; Koromia, G.A.; ElAmm, C.A.; Oliveira, G.H. Changes in the Association of Rising Infective Endocarditis With Mortality in People Who Inject Drugs. JAMA Cardiol. 2018, 3, 779–780. [Google Scholar] [CrossRef] [PubMed]
- Hidalgo-Tenorio C, Vinuesa D, Plata A. et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019, 18, 30. [Google Scholar]
- Bearnot, B.; Mitton, J.A.; Hayden, M.; Park, E.R. Experiences of care among individuals with opioid use disorder-associated endocarditis and their healthcare providers: Results from a qualitative study. J Subst Abuse Treat. 2019, 102, 16–22. [Google Scholar] [CrossRef]
- Leahey, P.A.; LaSalvia, M.T.; Rosenthal, E.S. High morbidity and mortality among patients with sentinel admission for injection drug use-related infective endocarditis. Open Forum Infect Dis. 2019, 6, ofz089. [Google Scholar] [CrossRef]
- Kadri, A.N.; Wilner, B.; Hernandez, A.V. Geographic trends, patient characteristics, and outcomes of infective endocarditis associated with drug abuse in the United States from 2002 to 2016. J Am Heart Assoc. 2019, 8. [Google Scholar] [CrossRef]
- Rohn, V.; Laca, B.; Horn, M.; Vlk, L.; Antonova, P.; Mosna, F. Surgery in drug use-associated infective endocarditis: long-term survival is negatively affected by recurrence. Interact Cardiovasc Thorac Surg. 2020, 30, 528–534. [Google Scholar] [CrossRef] [PubMed]
- Nguemeni Tiako MJ, Mori M, Bin Mahmood SU, Shioda K, Mangi A, Yun J. et al. Recidivism is the leading cause of death among intravenous drug users who underwent cardiac surgery for infective endocarditis. Semin Thorac Cardiovasc Surg. 2019, 31, 40–45. [Google Scholar] [CrossRef] [PubMed]
- Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, ESC Scientific Document Group et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015, 36, 3075–3128. [CrossRef]
- Miller, A.C.; Polgreen, P.M. Many Opportunities to Record, Diagnose, or Treat Injection Drug-related Infections Are Missed: A Population-based Cohort Study of Inpatient and Emergency Department Settings. Clin Infect Dis. 2019, 68, 1166–1175. [Google Scholar] [CrossRef] [PubMed]
- Gray, M.E.; Rogawski McQuade, E.T.; Scheld, W.M.; Dillingham, R.A. Rising rates of injection drug use associated infective endocarditis in Virginia with missed opportunities for addiction treatment referral: a retrospective cohort study. BMC Infect Dis. 2018, 18, 532. [Google Scholar] [CrossRef] [PubMed]
- Wurcel AG, Anderson JE, Chui KK. et al. Increasing infectious endocarditis admissions among young people who inject drugs. Open Forum Infect Dis 2016, 3, ofw157. [CrossRef]
- Straw S, Baig MW, Gillott R. et al. Long-term outcomes are poor in intravenous drug users following infective endocarditis, even after surgery. Clin Infect Dis Epub ahead of print. 2019.
- Mori M, Bin Mahmood SU, Schranz AJ. et al. Risk of reoperative valve surgery for endocarditis associated with drug use. J Thorac Cardiovasc Surg 2019.
- Hall R, Shaughnessy M, Boll G. et al. Drug Use and Postoperative Mortality Following Valve Surgery for Infective Endocarditis: A Systematic Review and Meta-analysis. Clin Infect Dis. 2019, 69, 1120–1129. [Google Scholar] [CrossRef]
- Baddour, L.M. , Wilson W.R., Bayer A.S.. et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015, 132, 1435–1486. [Google Scholar] [CrossRef]
- Hung, H.C. , Chen S.C., Chan K.C.. et al. Retrospective evaluation of infective endocarditis over ten years in Taiwan. J Heart Valve Dis. 2013, 22, 248–256. [Google Scholar] [PubMed]
- Weir, M.A. , Slater J., Jandoc R.. et al. The risk of infective endocarditis among people who inject drugs: a retrospective, population-based time series analysis. CMAJ. 2019, 191, E93–E99. [Google Scholar] [CrossRef] [PubMed]
- Akinosoglou, K.; Apostolakis, E.; Marangos, M.; Pasvol, G. Native valve right sided infective endocarditis. Eur J Intern Med. 2013, 24, 510–519. [Google Scholar] [CrossRef] [PubMed]
| PATIENTS CHARACTERISTICS | NO.(%) |
|---|---|
| SEX | |
| MALE | 32(74.4%) |
| FEMALE | 11(25.6%) |
| AGE | |
| <20 | 7(16.2%) |
| 20-30 | 21(48.8%) |
| 31-40 | 15(34.8%) |
| COMORBIDITIES | |
| HEPATOCELLULAR CARCINOMA | 2(4.6%) |
| HIV | 28(65.1%) |
| HEPATITIS C | 11(25.5%) |
| HEPATITIS B | 2(4.6%) |
| CHRONIC RENAL FAILURE | 1(2.3%) |
| HYPERTENSION | 3(6.9%) |
| CHRONIC ALCOHOLISM | 14(32.5%) |
| ESOPHAGEAL VARICES | 2(4.6%) |
| CELLULITIS | 16(37.2%) |
| NECROTIZING FASCIITIS | 1(2.3%) |
| AIDS | 2(4.6%) |
| STROKE | 4(9.3%) |
| SIFILIS | 1(2.3%) |
| URINARY TRACT INFECTIONS | 8(18.6%) |
| ORAL/VAGINAL CANDIDIASIS | 19(44.1%) |
| PNEUMONIA | 4(9.3%) |
| KAPOSI SARCOMA | 1(2.3%) |
| ETIOLOGICAL AGENTS ISOLATED IN BLOOD CULTURES | NO.(%) |
|---|---|
| STAPHYLOCOCCUS AUREUS | 24(55.9%) |
| ENTEROCOCCUS FAECALIS | 7(16.4%) |
| STREPTOCOCCUS MITIS | 6(13.9%) |
| STAPHYLOCOCCUS EPIDERMIDIS | 3(6.9%) |
| KLEBSIELLA PNEUMONIAE | 3(6.9%) |
| COMPLICATIONS ASSOCIATED WITH IE | NO.(%) |
|---|---|
| INTRACRANIAL HEMORRHAGE | 3(6.9%) |
| SEPSIS | 8(18.6%) |
| PNEUMONIA | 9(20.9%) |
| PULMONARY EDEMA | 7(16.2%) |
| RESPIRATORY DISTRESS | 7(16.2%) |
| CONGESTIVE HEART FAILURE | 5(11.6%) |
| VALVULAR VEGETATIONS | 10(23.2%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).